Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Ruby Khatun Khatun
    Ruby Khatun Khatun
      • Home
      • Ruby Khatun Khatun

      Articles By : Ruby Khatun Khatun

      Moderna, AstraZeneca heart drug succeeds early-stage trial

      Moderna, AstraZeneca heart drug succeeds early-stage trial

      Ruby Khatun Khatun17 Sept 2017 9:15 AM IST
      Biotech unicorn Moderna Therapeutics said on Thursday its heart drug, developed along with British drugmaker AstraZeneca met the main goal in an...
      No mid-term revision of stent prices before February 2018: NPPA

      No mid-term revision of stent prices before February 2018: NPPA

      Ruby Khatun Khatun16 Sept 2017 3:26 PM IST
      New Delhi: Drug pricing regulator NPPA on Friday ruled out a mid-term revision of coronary stent prices, saying it would revisit the matter in...
      Amgen gets FDA approval for Mvasi- first biosimilar to treat cancer

      Amgen gets FDA approval for Mvasi- first biosimilar to treat cancer

      Ruby Khatun Khatun16 Sept 2017 10:53 AM IST
      The U.S. Food and Drug Administration (FDA) approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple...
      Aspen to buy remaining AstraZeneca anaesthetic rights for up to 766 million dollar

      Aspen to buy remaining AstraZeneca anaesthetic rights for up to 766 million dollar

      Ruby Khatun Khatun16 Sept 2017 10:17 AM IST
      LONDON: AstraZeneca said on Thursday it had agreed to sell the U.S. rights to a portfolio of anaesthetics to South Africa's Aspen Group for up to $766...
      Halozyme to license drug delivery tech to Roche, Bristol-Myers

      Halozyme to license drug delivery tech to Roche, Bristol-Myers

      Ruby Khatun Khatun16 Sept 2017 9:55 AM IST
      U.S. drugmaker Halozyme Therapeutics Inc said on Thursday it would license its drug delivery technology to Bristol-Myers Squibb Co and Swiss drugmaker...
      Challenge of Allergan tribal patent deal in uncharted legal territory

      Challenge of Allergan tribal patent deal in uncharted legal territory

      Ruby Khatun Khatun16 Sept 2017 9:35 AM IST
      As generic drug manufacturers are gearing up to argue that a deal Allergan Plc made with a Native American tribe to shield patents from administrative...
      Impressed FDA panel unanimously recommends GSK shingles vaccine

      Impressed FDA panel unanimously recommends GSK shingles vaccine

      Ruby Khatun Khatun16 Sept 2017 9:15 AM IST
      A U.S. Food and Drug Administration (FDA) advisory panel on Wednesday voted 11-0 that the safety and efficacy of GlaxoSmithKline’s Shingrix shingles...
      CDSCO challenges FDC order in Supreme Court, Final hearing on the 19th Sept

      CDSCO challenges FDC order in Supreme Court, Final hearing on the 19th Sept

      Ruby Khatun Khatun15 Sept 2017 11:27 AM IST
      New Delhi: Through a recent notification, CDSCO, Ministry of Health and Family Welfare has announced that it (Union of India) had challenged the order...
      Lupin gets USFDA nod to market generic anti-bacterial drug

      Lupin gets USFDA nod to market generic anti-bacterial drug

      Ruby Khatun Khatun15 Sept 2017 10:46 AM IST
      New Delhi: Drug maker Lupin on Wednesday said it has received US health regulator's nod to market generic version of Flagyl tablets, a drug used to...
      Bayer gets FDA approval for Aliqopa (copanlisib) to treat adults with relapsed follicular lymphoma

      Bayer gets FDA approval for Aliqopa (copanlisib) to treat adults with relapsed follicular lymphoma

      Ruby Khatun Khatun15 Sept 2017 10:19 AM IST
      The U.S. Food and Drug Administration (FDA) granted accelerated approval to Aliqopa (copanlisib) for the treatment of adults with relapsed follicular...
      Sanofi indicates dupilumab could be used to treat nasal polyps

      Sanofi indicates dupilumab could be used to treat nasal polyps

      Ruby Khatun Khatun15 Sept 2017 10:17 AM IST
      PARIS: Sanofi’s chief executive said that its key drug dupilumab could possibly be used to treat nasal polyps as well as eczema and asthma.The FDA...
      UST Global invests in MyDoc, a Singapore-based digital health platform company

      UST Global invests in MyDoc, a Singapore-based digital health platform company

      Ruby Khatun Khatun15 Sept 2017 10:07 AM IST
      THIRUVANANTHAPURAM: UST Global has made a strategic investment in MyDoc, a Singapore-based digital health platform company, to expand its digital...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok